4//SEC Filing
Cranston Lynda Sarah 4
Accession 0001213900-20-016317
CIK 0001498382other
Filed
Jun 29, 8:00 PM ET
Accepted
Jun 30, 4:16 PM ET
Size
7.6 KB
Accession
0001213900-20-016317
Insider Transaction Report
Form 4
Cranston Lynda Sarah
Director
Transactions
- Other
Common Stock
2020-06-30−8→ 332 total(indirect: Held by J.G. Cranston & Associates, Inc.) - Award
Option (Right to Buy)
2020-06-26+39,567→ 75,000 totalExercise: $0.61Exp: 2029-09-05→ Common Stock (39,567 underlying)
Footnotes (3)
- [F1]The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock.
- [F2]On September 5, 2019, the reporting person received options to purchase 39,567 shares which were subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020.
- [F3]The shares subject to the option vest in twelve (12) equal monthly installments beginning on October 5, 2019.
Documents
Issuer
DelMar Pharmaceuticals, Inc.
CIK 0001498382
Entity typeother
Related Parties
1- filerCIK 0001633660
Filing Metadata
- Form type
- 4
- Filed
- Jun 29, 8:00 PM ET
- Accepted
- Jun 30, 4:16 PM ET
- Size
- 7.6 KB